pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
JOHNSON & JOHNSON ($JNJ) · news · pharmadog
← back to JOHNSON & JOHNSON
News mentioning $JNJ
106
stories
22d
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
22d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
22d
J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
endpoints
22d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
22d
Boston Scientific cuts guidance again after unveiling restructuring plan
fiercebiotech
22d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
24d
J&J proposes $5.5B talc settlement
endpoints
25d
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
25d
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
fiercebiotech
25d
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
28d
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
28d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
28d
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
29d
BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
biospace
29d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
29d
FDA clears Johnson & Johnson’s surgical robot for ‘the next era in surgery’
fiercebiotech
Jul 22, 26
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
Jul 22, 26
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
biospace
Jul 22, 26
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 21, 26
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
Jul 20, 26
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
biospace
Jul 20, 26
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal
endpoints
Jul 20, 26
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
Jul 18, 26
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
fiercebiotech
Jul 17, 26
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
fiercebiotech
Jul 16, 26
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
biopharma dive
Jul 16, 26
‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
fiercebiotech
Jul 16, 26
J&J sees Spravato sales surge as psychedelic competitors loom
biospace
← prev
page 2 of 4
next →
